AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3604970 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructo-oligosaccharide (5 g tid for 12 d)
Number of subjects: 15
Study 3604970 — intervention group
Group type: COMPARATOR
Intervention: Sucrose (5 g tid for 12 d)
Number of subjects: 15
Study 3604970 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructo-oligosaccharide (10 g)
Number of subjects: 15
Study 30138384 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined navigated laser photocoagulation and intravitreal ranibizumab
Number of subjects: 0
Study 30138384 — intervention group
Group type: COMPARATOR
Intervention: Ranibizumab monotherapy
Number of subjects: 0
Study 27009936 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane
Number of subjects: 490
Study 27009936 — intervention group
Group type: COMPARATOR
Intervention: Letrozole
Number of subjects: 490
Study 25201934 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy‐oriented anger management and stress control program (5 sessions, 90 minutes each)
Number of subjects: 350
Study 25201934 — intervention group
Group type: COMPARATOR
Intervention: Standard quit program
Number of subjects: 350
Study 25201934 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy‐oriented anger management and stress control program
Number of subjects: 350
Study 22675955 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoxicam 20 mg
Number of subjects: 120
Study 22675955 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol 1 g
Number of subjects: 120
Study 22675955 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 20029974 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiac axis infusion chemotherapy combined with radiotherapy (CAI/RT)
Number of subjects: 120
Study 20029974 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant treatment (Control)
Number of subjects: 120
Study 17468012 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceptual priming during the incidental encoding phase
Number of subjects: 0
Study 17468012 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceptual priming
Number of subjects: 0
Study 17468012 — intervention group
Group type: COMPARATOR
Intervention: Control words (not explicitly defined)
Number of subjects: 0
Study 15968653 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel spectroscopic imaging method with high spectral and spatial resolution; improved sensitivity using a binomial 1 1 excitation pulse; narrow spectral bandwidth (6 ppm); measurement time acceptable.
Number of subjects: 0
Study 15968653 — intervention group
Group type: EXPERIMENTAL
Intervention: Post‐detection data processing scheme for correction of spectral artifacts.
Number of subjects: 0
Study 12771603 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombin III (Kybernin P)
Number of subjects: 17
Study 12771603 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 11036377 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy
Number of subjects: 1406
Study 11036377 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical teaching initiatives (TME concept workshops)
Number of subjects: 1406
Study 8774196 — intervention group
Group type: EXPERIMENTAL
Intervention: Otolaryngology trainee assessment
Number of subjects: 100
Study 8774196 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaesthetist assessment
Number of subjects: 100
Study 8774196 — intervention group
Group type: COMPARATOR
Intervention: Combined assessments
Number of subjects: 100
Study 1316401 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-sodium diet (LSD) with lactose capsules
Number of subjects: 20
Study 1316401 — intervention group
Group type: COMPARATOR
Intervention: Normal-sodium diet (NSD) with salt capsules
Number of subjects: 20
Study 3902954 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography (U/S)
Number of subjects: 14
Study 3902954 — intervention group
Group type: COMPARATOR
Intervention: Oral cholecystography (OCG)
Number of subjects: 14
Study 3902954 — intervention group
Group type: EXPERIMENTAL
Intervention: Life table analysis (1 U/S)
Number of subjects: 14
Study 3902954 — intervention group
Group type: COMPARATOR
Intervention: Life table analysis (1 OCG)
Number of subjects: 14
Study 3902954 — intervention group
Group type: EXPERIMENTAL
Intervention: Life table analysis (2 successive U/S studies)
Number of subjects: 14
Study 3902954 — intervention group
Group type: EXPERIMENTAL
Intervention: Life table analysis (1 U/S plus 1 OCG)
Number of subjects: 14
Study 29888656 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R and Lactobacillus rhamnosus CLR2, 2 capsules daily containing 50×10^9 cfu of live organisms
Number of subjects: 113
Study 29888656 — intervention group
Group type: COMPARATOR
Intervention: Placebo, 2 capsules daily
Number of subjects: 113
Study 26613768 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 324
Study 26613768 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab
Number of subjects: 324
Study 23374652 — intervention group
Group type: EXPERIMENTAL
Intervention: PiCCO monitoring
Number of subjects: 708
Study 21427425 — intervention group
Group type: COMPARATOR
Intervention: Continuous therapy (CT, n = 65)
Number of subjects: 156
Study 21427425 — intervention group
Group type: COMPARATOR
Intervention: CD4‐guided cART (n = 91)
Number of subjects: 156
Study 18834717 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat vegan diet
Number of subjects: 93
Study 18834717 — intervention group
Group type: COMPARATOR
Intervention: Diet following 2003 American Diabetes Association guidelines
Number of subjects: 93
Study 17555947 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 522
Study 17555947 — intervention group
Group type: COMPARATOR
Intervention: SOC
Number of subjects: 522
Study 15234055 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrafractionated radiotherapy (0.5 Gy TDS: 4‐h gap)
Number of subjects: 8
Study 15234055 — intervention group
Group type: COMPARATOR
Intervention: Conventionally fractionated radiotherapy (1.5 Gy/day)
Number of subjects: 8
Study 11696466 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib
Number of subjects: 28000
Study 11696466 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28000
Study 11696466 — intervention group
Group type: COMPARATOR
Intervention: Non-naproxen NSAIDs
Number of subjects: 28000
Study 11696466 — intervention group
Group type: COMPARATOR
Intervention: Naproxen
Number of subjects: 28000
Study 9562293 — intervention group
Group type: COMPARATOR
Intervention: C (caffeine 5 mg x kg[-1])
Number of subjects: 8
Study 9562293 — intervention group
Group type: COMPARATOR
Intervention: E (ephedrine 1 mg x kg[-1])
Number of subjects: 8
Study 9562293 — intervention group
Group type: COMPARATOR
Intervention: C+E (caffeine and ephedrine combination)
Number of subjects: 8
Study 9562293 — intervention group
Group type: COMPARATOR
Intervention: P (placebo)
Number of subjects: 8
Study 9562293 — intervention group
Group type: COMPARATOR
Intervention: C+E
Number of subjects: 8
Study 9562293 — intervention group
Group type: COMPARATOR
Intervention: C
Number of subjects: 8
Study 9562293 — intervention group
Group type: COMPARATOR
Intervention: C+E and C
Number of subjects: 8
Study 7936513 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate 10 mg/day for 14 days every 28 days
Number of subjects: 80
Study 7936513 — intervention group
Group type: COMPARATOR
Intervention: Medroxyprogesterone acetate 10 mg/day for 28 of 84 days
Number of subjects: 80
Study 7936513 — intervention group
Group type: COMPARATOR
Intervention: Medroxyprogesterone acetate 10 mg/day for 14 days every 84 days
Number of subjects: 80
Study 7936513 — intervention group
Group type: COMPARATOR
Intervention: Medroxyprogesterone acetate (all groups)
Number of subjects: 80
Study 7936513 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (less than monthly)
Number of subjects: 80
Study 7936513 — intervention group
Group type: COMPARATOR
Intervention: Medroxyprogesterone acetate (monthly)
Number of subjects: 80
Study 2447257 — intervention group
Group type: EXPERIMENTAL
Intervention: Early high-dose phenobarbital treatment (15 mg/kg IV at 110 minutes, followed by 15 mg/kg after 4 hours, then 5 mg/kg every 24 hours for 5 days)
Number of subjects: 0
Study 2447257 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 2447257 — intervention group
Group type: EXPERIMENTAL
Intervention: Early high-dose phenobarbital treatment
Number of subjects: 0
Study 30335188 — intervention group
Group type: EXPERIMENTAL
Intervention: Survivorship Planning Consultation (SPC)
Number of subjects: 198
Study 30335188 — intervention group
Group type: COMPARATOR
Intervention: Time-controlled Wellness Rehabilitation Consultation (WRC)
Number of subjects: 198
Study 26337539 — intervention group
Group type: EXPERIMENTAL
Intervention: Bi-weekly alternating ranibizumab/bevacizumab injections
Number of subjects: 18
Study 25715991 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrillation testing
Number of subjects: 2500
Study 25715991 — intervention group
Group type: COMPARATOR
Intervention: No defibrillation testing
Number of subjects: 2500
Study 23720852 — intervention group
Group type: EXPERIMENTAL
Intervention: Easyhaler (budesonide and formoterol)
Number of subjects: 0
Study 23720852 — intervention group
Group type: COMPARATOR
Intervention: Aerolyser inhaler
Number of subjects: 0
Study 21138462 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone supplementation (160 mg/day of oral testosterone undecanoate)
Number of subjects: 237
Study 21138462 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 237
Study 18277833 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing sessions with a motivational interviewing‐trained nurse
Number of subjects: 0
Study 18277833 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Number of subjects: 0
Study 21494076 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic polymorphism at codon 10 of the TGF‐β1 gene
Number of subjects: 301
Study 15760313 — intervention group
Group type: EXPERIMENTAL
Intervention: Buscopan suppositories
Number of subjects: 200
Study 15760313 — intervention group
Group type: COMPARATOR
Intervention: Control (no drug)
Number of subjects: 200
Study 11962564 — intervention group
Group type: EXPERIMENTAL
Intervention: Community education program (18-month, multicomponent)
Number of subjects: 44
Study 9845395 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg
Number of subjects: 1262
Study 9845395 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 10 mg
Number of subjects: 1262
Study 9845395 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1262
Study 9845395 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg (ulcer-like dyspepsia)
Number of subjects: 1262
Study 9845395 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 10 mg (ulcer-like dyspepsia)
Number of subjects: 1262
Study 9845395 — intervention group
Group type: COMPARATOR
Intervention: Placebo (ulcer-like dyspepsia)
Number of subjects: 1262
Study 9845395 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg (reflux-like dyspepsia)
Number of subjects: 1262
Study 9845395 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 10 mg (reflux-like dyspepsia)
Number of subjects: 1262
Study 9845395 — intervention group
Group type: COMPARATOR
Intervention: Placebo (reflux-like dyspepsia)
Number of subjects: 1262
Study 9845395 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 1262
Study 7814301 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilvadipine (16 mg daily)
Number of subjects: 23
Study 7814301 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 2910681 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon
Number of subjects: 20
Study 2910681 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon-(1-21)-peptide
Number of subjects: 20
Study 22438 — intervention group
Group type: EXPERIMENTAL
Intervention: Glafenine (Glifanan)
Number of subjects: 20
Study 22438 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30572426 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive education on hand hygiene
Number of subjects: 6484
Study 30572426 — intervention group
Group type: COMPARATOR
Intervention: General education (Control)
Number of subjects: 6484
Study 27553181 — intervention group
Group type: EXPERIMENTAL
Intervention: Elosulfase alfa 2.0 mg/kg/week
Number of subjects: 0
Study 27553181 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated patients from MorCAP)
Number of subjects: 0
Study 23668849 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate exercise
Number of subjects: 23
Study 23668849 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous exercise
Number of subjects: 23
Study 23668849 — intervention group
Group type: COMPARATOR
Intervention: Passive control
Number of subjects: 23
Study 22167077 — intervention group
Group type: EXPERIMENTAL
Intervention: Human milk mixed with a multinutrient fortifier
Number of subjects: 39
Study 22167077 — intervention group
Group type: COMPARATOR
Intervention: Human milk alone (control)
Number of subjects: 39
Study 20572865 — intervention group
Group type: EXPERIMENTAL
Intervention: Lingual brackets
Number of subjects: 0
Study 20572865 — intervention group
Group type: COMPARATOR
Intervention: Buccal brackets
Number of subjects: 0
Study 18549330 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (Humira)
Number of subjects: 3
Study 15994264 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin-based chemotherapy + supportive care (C)
Number of subjects: 194
Study 15994264 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive care alone (NoC)
Number of subjects: 194
Study 12899545 — intervention group
Group type: EXPERIMENTAL
Intervention: ROBODOC femoral milling system
Number of subjects: 71
Study 12899545 — intervention group
Group type: COMPARATOR
Intervention: Conventional cementless THA surgery
Number of subjects: 71
Study 10093002 — intervention group
Group type: EXPERIMENTAL
Intervention: CR2194 (spiroglumide) 1, 2.5 or 7.5 mg kg‐1 h‐1
Number of subjects: 0
Study 10093002 — intervention group
Group type: EXPERIMENTAL
Intervention: CR2194 (7.5 mg kg‐1 h‐1)
Number of subjects: 0
Study 10093002 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 0
Study 10093002 — intervention group
Group type: EXPERIMENTAL
Intervention: CR2194 (spiroglumide)
Number of subjects: 0
Study 8604591 — intervention group
Group type: EXPERIMENTAL
Intervention: desferrioxamine B (100 mg/kg/day) as a single agent
Number of subjects: 158
Study 8604591 — intervention group
Group type: EXPERIMENTAL
Intervention: desferrioxamine B in addition to standard quinine-based therapy
Number of subjects: 158
Study 8604591 — intervention group
Group type: COMPARATOR
Intervention: placebo in addition to standard quinine-based therapy
Number of subjects: 158
Study 1954075 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilevalol
Number of subjects: 18
Study 7023799 — intervention group
Group type: EXPERIMENTAL
Intervention: Ionic contrast medium
Number of subjects: 0
Study 7023799 — intervention group
Group type: COMPARATOR
Intervention: Non-ionic contrast medium
Number of subjects: 0
Study 30586757 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 7020
Study 30586757 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7020
Study 29287876 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative visiting operation room (PVOR)
Number of subjects: 69
Study 29287876 — intervention group
Group type: COMPARATOR
Intervention: Routine preoperative visit (RV)
Number of subjects: 69
Study 29287876 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine preoperative visit plus propofol (RP)
Number of subjects: 69
Study 27809905 — intervention group
Group type: EXPERIMENTAL
Intervention: Peyton's four-step approach (PG)
Number of subjects: 95
Study 27809905 — intervention group
Group type: COMPARATOR
Intervention: Conventional teaching (CG)
Number of subjects: 95
Study 25142002 — intervention group
Group type: EXPERIMENTAL
Intervention: ixmyelocel-T (administered intramyocardially via minithoracotomy)
Number of subjects: 61
Study 25142002 — intervention group
Group type: EXPERIMENTAL
Intervention: ixmyelocel-T (administered intramyocardially using the NOGA Myostar catheter)
Number of subjects: 61
Study 25142002 — intervention group
Group type: COMPARATOR
Intervention: Standard of care control
Number of subjects: 61
Study 22896665 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg BMS‐663068 plus 100 mg ritonavir every 12 hours (Q12H)
Number of subjects: 50
Study 22896665 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 mg BMS‐663068 plus 100 mg ritonavir every bedtime
Number of subjects: 50
Study 22896665 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 mg BMS‐663068 plus 100 mg ritonavir Q12H
Number of subjects: 50
Study 22896665 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 mg BMS‐663068 Q12H plus 100 mg ritonavir every morning
Number of subjects: 50
Study 22896665 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 mg BMS‐663068 Q12H
Number of subjects: 50
Study 22896665 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 50
Study 19747930 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal administration of oxytocin
Number of subjects: 27
Study 19747930 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 17591623 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood glucose self monitoring with advice for patients to contact their doctor for interpretation of results, in addition to usual care (n=150)
Number of subjects: 453
Study 17591623 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood glucose self monitoring with additional training of patients in interpretation and application of the results (n=151)
Number of subjects: 453
Study 17591623 — intervention group
Group type: COMPARATOR
Intervention: Standardised usual care with measurements of HbA1c every three months (n=152)
Number of subjects: 453
Study 15642546 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents
Number of subjects: 1080
Study 15642546 — intervention group
Group type: COMPARATOR
Intervention: Bare stents
Number of subjects: 1080
Study 12372673 — intervention group
Group type: EXPERIMENTAL
Intervention: IR-low (HOMA: 36.3 +/- 1.7)
Number of subjects: 75
Study 12372673 — intervention group
Group type: EXPERIMENTAL
Intervention: IR-medium (HOMA: 62.6 +/- 1.6)
Number of subjects: 75
Study 12372673 — intervention group
Group type: EXPERIMENTAL
Intervention: IR-high (HOMA: 123.1 +/- 12.8)
Number of subjects: 75
Study 12372673 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between IR and hemodynamic measurements
Number of subjects: 75
Study 12379064 — intervention group
Group type: EXPERIMENTAL
Intervention: Ximelagatran, 24 mg twice daily for 7 to 12 days
Number of subjects: 680
Study 12379064 — intervention group
Group type: COMPARATOR
Intervention: Warfarin (target INR 2.5, range 1.8 to 3.0), starting on the evening of the day of surgery
Number of subjects: 680
Study 12379064 — intervention group
Group type: EXPERIMENTAL
Intervention: Ximelagatran
Number of subjects: 680
Study 12379064 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 680
Study 9822045 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxonidine (0.2- to 0.4-mg)
Number of subjects: 14
Study 9822045 — intervention group
Group type: COMPARATOR
Intervention: Cilazapril (2.5- to 5.0-mg)
Number of subjects: 14
Study 9822045 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxonidine
Number of subjects: 14
Study 9822045 — intervention group
Group type: COMPARATOR
Intervention: Cilazapril
Number of subjects: 14
Study 8017470 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 20 mg once daily for 6 weeks, then 20 mg twice daily for an additional 6 weeks
Number of subjects: 66
Study 2637069 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (short-acting benzodiazepine)
Number of subjects: 12
Study 2637069 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentazocin or Piritramid (analgesics)
Number of subjects: 12
Study 334185 — intervention group
Group type: COMPARATOR
Intervention: 300 mg of aspirin
Number of subjects: 140
Study 334185 — intervention group
Group type: COMPARATOR
Intervention: 600 mg of aspirin
Number of subjects: 140
Study 334185 — intervention group
Group type: COMPARATOR
Intervention: 1200 mg of aspirin
Number of subjects: 140
Study 334185 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg of 43‐715 (1‐isopropyl‐4‐phenyl-7-methyl-2 (1H) quinazolone)
Number of subjects: 140
Study 334185 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg of 43‐715 (1‐isopropyl‐4‐phenyl-7-methyl-2 (1H) quinazolone)
Number of subjects: 140
Study 334185 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg of 43‐715 (1‐isopropyl‐4‐phenyl-7-methyl-2 (1H) quinazolone)
Number of subjects: 140
Study 31555976 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutraceutical treatment (Omega‐3: EPA 1 g/DHA 656 mg, SAMe, zinc, 5‐HTP, folinic acid, and co‐factors)
Number of subjects: 158
Study 31555976 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study 29490560 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate physical exercise in an aquatic environment (1-hour sessions, 3 days a week)
Number of subjects: 0
Study 29490560 — intervention group
Group type: COMPARATOR
Intervention: Sedentary women (control group)
Number of subjects: 0
Study 29490560 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate physical exercise in an aquatic environment
Number of subjects: 0
Study 27804048 — intervention group
Group type: EXPERIMENTAL
Intervention: Femtosecond laser-assisted Keraring ICRS (Group A)
Number of subjects: 44
Study 27804048 — intervention group
Group type: EXPERIMENTAL
Intervention: MyoRing (Group B)
Number of subjects: 44
Study 25705872 — intervention group
Group type: COMPARATOR
Intervention: 8 weeks nicotine patch treatment
Number of subjects: 525
Study 25705872 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 weeks nicotine patch treatment
Number of subjects: 525
Study 25705872 — intervention group
Group type: EXPERIMENTAL
Intervention: 52 weeks nicotine patch treatment
Number of subjects: 525
Study 23518148 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib therapy (2nd-line)
Number of subjects: 20
Study 21460008 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentavalent antimony treatment with early antihelminthic therapy
Number of subjects: 90